(S)-A-METHYL-A-[[[(4-NITROPHENYL)AMINO]CARBONYL]AMINO]-N-[[1-(2-PYRIDINYL)CYCLOHEXYL]METHYL]-1H-INDOLE-3-PROPANAMIDE
- Product Name
- (S)-A-METHYL-A-[[[(4-NITROPHENYL)AMINO]CARBONYL]AMINO]-N-[[1-(2-PYRIDINYL)CYCLOHEXYL]METHYL]-1H-INDOLE-3-PROPANAMIDE
- CAS No.
- 204066-82-0
- Chemical Name
- (S)-A-METHYL-A-[[[(4-NITROPHENYL)AMINO]CARBONYL]AMINO]-N-[[1-(2-PYRIDINYL)CYCLOHEXYL]METHYL]-1H-INDOLE-3-PROPANAMIDE
- Synonyms
- PD 168368;(2S)-3-(1H-INDOL-3-YL)-2-METHYL-2-[(4-NITROPHENYL)CARBAMOYLAMINO]-N-[(1-PYRIDIN-2-YLCYCLOHEXYL)METHYL]PROPANAMIDE;(S)-α-Methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-1H-indole-3-propanamide;(S)-A-METHYL-A-[[[(4-NITROPHENYL)AMINO]CARBONYL]AMINO]-N-[[1-(2-PYRIDINYL)CYCLOHEXYL]METHYL]-1H-INDOLE-3-PROPANAMIDE;1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)-
- CBNumber
- CB32453427
- Molecular Formula
- C31H34N6O4
- Formula Weight
- 554.64
- MOL File
- 204066-82-0.mol
(S)-A-METHYL-A-[[[(4-NITROPHENYL)AMINO]CARBONYL]AMINO]-N-[[1-(2-PYRIDINYL)CYCLOHEXYL]METHYL]-1H-INDOLE-3-PROPANAMIDE Property
- Boiling point:
- 819.7±65.0 °C(Predicted)
- Density
- 1.300±0.06 g/cm3(Predicted)
- storage temp.
- Store at +4°C
- solubility
- DMF: 10 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.3 mg/ml
- form
- A crystalline solid
- pka
- 11.60±0.46(Predicted)
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- 17920
- Product name
- PD 168368
- Purity
- ≥95%
- Packaging
- 500μg
- Price
- $32
- Updated
- 2024/03/01
- Product number
- 17920
- Product name
- PD 168368
- Purity
- ≥95%
- Packaging
- 1mg
- Price
- $61
- Updated
- 2024/03/01
- Product number
- 17920
- Product name
- PD 168368
- Purity
- ≥95%
- Packaging
- 5mg
- Price
- $243
- Updated
- 2024/03/01
- Product number
- 17920
- Product name
- PD 168368
- Purity
- ≥95%
- Packaging
- 10mg
- Price
- $347
- Updated
- 2024/03/01
- Product number
- 4346CR
- Product name
- CID9937534
- Packaging
- 10mg
- Price
- $484
- Updated
- 2021/12/16
(S)-A-METHYL-A-[[[(4-NITROPHENYL)AMINO]CARBONYL]AMINO]-N-[[1-(2-PYRIDINYL)CYCLOHEXYL]METHYL]-1H-INDOLE-3-PROPANAMIDE Chemical Properties,Usage,Production
Uses
PD 168368 is a potent, competitive, and selective neuromedin B receptor (NMB-R) antagonist with the Ki of 15–45 nM[1]. PD 168368 is neuromedin B receptor (NMBR; IC50=96 nM) / gastrin-releasing peptide receptor (GRPR IC50=3500 nM) antagonist[2]. PD 168368 also is a mixed FPR1/FPR2/FPR3 agonist with EC50s of 0.57, 0.24, and 2.7 nM, respectively[3].
Biological Activity
Potent neuromedin B receptor antagonist (NMB-R, BB 1 ) (IC 50 = 40 nM) that displays ~ 40-fold selectivity over the gastrin-releasing peptide receptor (GRP-R, BB 2 ) and > 300-fold selectivity over BRS-R (bb 3 ). Antagonizes neuromedin B-stimulated calcium release and inhibits proliferation of rat glioma cells (IC 50 = 2 μ M).
in vivo
PD 168368 (PD168368) potently inhibits in vivo metastasis of breast cancer. PD 168368 (1.2 mg/kg; intraperitoneal injection for 30 days) inhibits metastasis of breast cancer in mice[4].
| Animal Model: | Female BALB/c-nude mice (age 8-10 weeks) bearing MDA-MB-231 xenograft model[4] |
| Dosage: | 1.2 mg/kg |
| Administration: | Intraperitoneal injection for 30 days |
| Result: | No metastatic tumor nodules were observed in lungs of PD 168368-treated mice compared to PEG-injected mice. |
References
[1] R R Ryan, et al. Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11. PMID:10454496
[2] K Tokita, et al. Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368. J Biol Chem. 2001 Jan 5;276(1):495-504. DOI:10.1074/jbc.M006059200
[3] Igor A Schepetkin, et al. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors. Mol Pharmacol. 2011 Jan;79(1):77-90. DOI:10.1124/mol.110.068288
[4] Hyun-Joo Park, et al. Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells. Int J Oncol. 2016 Sep;49(3):934-42. DOI:10.3892/ijo.2016.3590